ALK and non-small cell lung carcinoma: The promising and striking result of the PROFILE 1007 trial led to the phase III PROFILE 1014 clinical study, which aimed to assess the efficacy of the ALK inhibitor crizotinib compared to standard chemotherapy with pemetrexed plus platinum as the first-line treatment for metastatic ALK-rearranged NSCLC patients.